

REVENUE GROWTH

	2015	2016	2017	3-Yr CAGR
Total Company				
Reported Sales Growth	-2%	3%	9%	3%
Currency Impact	7%	2%	-	
Currency Neutral Sales Growth	5%	5%	9%	6%
Adjusted EPS Growth	3%	5%	7%	5%
Currency Impact	7%	1%	2%	
Currency Neutral Adjusted EPS Growth	11%	6%	9%	8%

The Company uses non-GAAP financial measures such as currency neutral sales (which eliminates the effects that result from translating its international sales in U.S. dollars) as the Company believes that these non-GAAP financial measures provide investors with an overall perspective of the period-to-period performance of our core business. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. These non-GAAP measures may not be comparable to similarly titled measures used by other companies.

ADJUSTED NET INCOME

(IN U.S. \$)	2013	2014	2015	2016	2017
As Reported Net Income	354	415	419	405	296
Restructuring and Other Charges	5	4	5	0	14
Operational Improvement Initiative Costs	3	2	1	2	1
Patent Litigation Settlement	-	-	-	-	-
Gain on Asset Sale	(9)	(0)	-	-5	0
Accelerated Contingent Consideration	-	-	7	-	0
Acquisition Related Costs	-	-	12	8	14
Tax Settlements	-	-	(10)	-	-
Spanish Tax Settlement	-	-	-	-	-
Spanish Capital Tax Charge Reversal	-	-	(8)	-	-
Spanish Tax Charges	15	(4)	-	-	-
Integration Related Costs	-	-	-	-	3
Tax Assessment	-	-	-	-	3
FDA Mandated Product Recall	-	-	-	-	7
UK Pension Settlement Charges	-	-	-	-	2
CTA Realization	-	-	-	-	(12)
U.S. Tax Reform	-	-	-	-	139
Legal Charges/Credits	-	-	-	31	1
Adjusted Net Income	368	416 *	426	441	468

*Item does not foot due to rounding

ADJUSTED TOTAL PAYOUT RATIO AS PERCENTAGE OF ADJUSTED NET INCOME

(IN U.S. \$)	2013	2014	2015	2016	2017
Dividend Payment	87	133	159	185	206
Adjustment Due to Timing of Payment	28	-	-	-	-
Adjusted Dividend Payment	115	133	159	185	206
Share Repurchases	51	88	122	127	58
Adjusted Total Payout as Percentage of Net Income	166	221	281	312	264
Adjusted Net Income Payout	45%	53%	66%	71%	56%

The Company uses non-GAAP financial measures such as Adjusted Net Income and Adjusted Net Income Payout (which excludes restructuring and other charges, operational improvement initiative costs, FDA mandated product recall charges, UK pension settlement charges, tax assessment, integration related costs, acquisition related costs, legal charges/credits and gain on sale of asset) as the Company believes that these non-GAAP financial measures provide investors with an overall perspective of the period-to-period performance of our core business. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. These non-GAAP measures may not be comparable to similarly titled measures used by other companies.